@article{5749225c80f4422598610994d2035e6e,
title = "A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigm",
abstract = "Cell surfaces display a wide array of molecules that confer identity. While flow cytometry and cluster of differentiation (CD) markers have revolutionized cell characterization and purification, functionally heterogeneous cellular subtypes remain unresolvable by the CD marker system alone. Using hematopoietic lineages as a paradigm, we leverage the extraordinary molecular diversity of heparan sulfate (HS) glycans to establish cellular “glycotypes” by utilizing a panel of anti-HS single-chain variable fragment antibodies (scFvs). Prospective sorting with anti-HS scFvs identifies functionally distinct glycotypes within heterogeneous pools of mouse and human hematopoietic progenitor cells and enables further stratification of immunophenotypically pure megakaryocyte–erythrocyte progenitors. This stratification correlates with expression of a heptad of HS-related genes that is reflective of the HS epitope recognized by specific anti-HS scFvs. While we show that HS glycotyping provides an orthogonal set of tools for resolution of hematopoietic lineages, we anticipate broad utility of this approach in defining and isolating novel, viable cell types across diverse tissues and species.",
author = "Piszczatowski, {Richard T.} and Emily Schwenger and Sriram Sundaravel and Stein, {Catarina M.} and Yang Liu and Pamela Stanley and Amit Verma and Deyou Zheng and Seidel, {Ronald D.} and Almo, {Steven C.} and Townley, {Robert A.} and B{\"u}low, {Hannes E.} and Ulrich Steidl",
note = "Funding Information: Disclosures: A. Verma reported “other” from Stelexis and Bakx Therapeutics and grants from Jannsen, BMS, Prelude, and Curis outside the submitted work. S.C. Almo, R.A. Townley, R.D. Seidel, R.T. Piszczatowski, U. Steidl, and H.E. B{\"u}low reported a patent to an antibody-based method to identify, purify, and manipulate cell types and processes pending. U. Steidl reported grants from GlaxoSmithKline, Bayer Healthcare, Aileron Funding Information: We thank S. Taylor, J.C. Wheat, and O. Bohorquez for their guidance and technical expertise. We also thank S. Rao Nar-ayanagari and D. Sun of the Stem Cell Isolation and Xenotransplantation Core Facility (funded by NYSTEM grant #C029154) of the Gottesman Institute for Stem Cell and Regenerative Medicine Research for expert technical support, D. Reynolds from the Genomics Core Facility, J. Zhang from the Flow Cytometry Core Facility, P. Schultes for technical assistance, and the Einstein Macromolecular Therapeutics Development Facility, all supported by the Montefiore Einstein Cancer Center (National Institutes of Health [NIH] grant P30CA013330). Funding Information: This work was supported by an NIH grant to U. Steidl and H.E. B{\"u}low (U01CA241981), a Medical Scientist Training Programs training grant to R.T. Piszczatowski (T32GM007288), National Cancer Institute Fellowship to R.T. Piszczatowski (F30CA217063), an NYSTEM training grant fellowship to E. Schwenger (N14I-006), an NIH grant to S. Sundaravel (K00CA223044), as well as NIH grant R35CA253127 (to U. Steidl). This work was supported by Jane A. and Myles P. Dempsey. U. Steidl is the Diane and Arthur B. Belfer Scholar in Cancer Research. S.C. Almo is the Wollowick Family Foundation Chair in Immunology. Publisher Copyright: {\textcopyright} 2022 Piszczatowski et al.",
year = "2022",
month = nov,
day = "7",
doi = "10.1084/jem.20212552",
language = "English (US)",
volume = "219",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "11",
}